Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immucor CEO De Chirico

This article was originally published in The Gray Sheet

Executive Summary

Chairman Edward Gallup will take over CEO duties "on an interim basis" from Gioacchino De Chirico while the firm conducts an internal investigation related to "alleged improper cash payments" by Immucor and other firms, made "in exchange for favorable contract awards" by an Italian hospital, the firm says. De Chirico will retain his other title of president during the investigation, which parallels a criminal investigation by Italian authorities. The hospital administrator apparently had received an improperly documented payment of about $17,000 to organize an Immucor-sponsored convention, according to the company...

You may also be interested in...



FDA Warning Letter Slams Pfizer Site In India On Sterility Testing, Environmental Monitoring

Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.

Gilead Moves Into Microbiome In Deal With Second Genome

Gilead lands on Second Genome as its first partner to apply microbiome analysis to pipeline assets to look for biomarkers. Companies also team up on GI drug discovery.

Warning Letter Close-Outs – March 2020

The US FDA released five device-related close-out letters in March.

UsernamePublicRestriction

Register

MT021141

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel